Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety Comparison of CKD-828 vs Co-administered Components in Healthy Adults
NCT05834595Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan + levamlodipine in hypertension (HTN) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started May 2023; status: completed.
02
Drugs
telmisartan + levamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05834595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05834595.